Nanotechnology : Biotechnology, Companies and Institutions

Nanoscience Technologies, Inc.

Benj — Sun, 27 Aug 2006 15:12:55 +0100

Ticker Id

Web url

http://www.nanoscience-tech.com/index1.htm

Contact Email

Short description

Street address

45 Rockefeller Plaza, Suite 2000 #43

Zip or postal code

10111

Telephone

212 332 3443

Fax

Foundation date

Ceo, president

David Keenan

Number of employees

Long description

The DNA nanotechnology research being pursued in the Seeman Laboratory address virtually all potential areas of nanotechnology commercialization and the Company has identified viable revenue models with which to deploy the considerable intellectual property under their control. Due to the unpredictable timelines of the research effort as well as the tempo and increasing momentum of outside interests in the technology, the sequence of revenue opportunities are difficult to forecast.

The Company is targeting collaborative agreements with industry partners within the next three to four years. Industry is already beginning to rapidly align itself with the limited key university research teams to acquire a knowledge base not accessible in the private sector. University research teams are years ahead of the industrial sector in knowledge about nanotechnology and how to deploy its promising applications that will change the shape of entire industries worldwide. Those who don’t embrace it immediately and acquire the knowledge necessary to retool their products, methods, and strategies necessary to integrate this technology risk losing a segment of their market or their entire business. Nanoscience Technologies is a founder in this new industrial revolution and has invaluable scientific knowledge with corresponding intellectual property to provide a critical collaboration with a select few partners.

The Company will provide the ability for a limited number of industrial partners to pursue early research issues and protocols, and develop what will become in-house research methodologies for nanotechnology based products while allowing these companies to successfully continue on their course with their current market efforts. The industrial complex is focused on near-term market objectives necessitated by the need to maintain market share and to address investor pressures on the bottom line. For most companies, the cost to properly fund an in-house research effort for products that may not be realized commercially during the next five to ten years is prohibitive. In addition, the private sector does not have access to the skills bank to mount the dynamics and the many development phases of such a research effort. In the final analysis their market future lies with the knowledge base in the university sector. In collaboration with our partners, Nanoscience Technologies will review the knowledge base and intellectual properties available. For those industrial efforts specifically in-line with the research and development initiatives of the Seeman Laboratory, the Company is targeting to reach an accord on a fee basis to assist the select companies to lay the framework for potential new processes and products. As well, the Company will identify research venues relative to DNA nanotechnology for integration in the prospective partner’s current products offerings to ensure that they remain competitive in the nano driven world to come.

In due course, various NYU developing technologies will come to fruition and be ready for commercial deployment. There are presently significant efforts underway in nanoarchitecture that will potentially effectively address medical industry venues such as drug leads as well as other key technologies, such as nanomotors. The value lies in a range of applications from aiding in self-assembly routines to electronic switching which will attract commercial partners and allow the Company to execute sub-licensing agreements for this intellectual property. These opportunities will be addressed by on-staff licensing professionals and their technical support staff that will liaise between the NYU research team and the prospective commercial partners. As these opportunities unfold in varying timelines for various commercial applications, the Company will effectively manage these opportunities.

Another key revenue prospect for the Company are the initiatives of various government agencies. On a global scale the US government appears to have committed more funds to nanotechnology research than any other government internationally. Nanotechnology relative to the military and national defense is clearly a key venue. One of the first government agency funding events for the Seeman Laboratory was the Department of the Navy based on their early recognition of the long term strategic military benefits that may evolve from the technology. The Seeman Laboratory is internationally recognized as a leader in their field and clearly presents a value proposition for government development initiatives in various agencies. The Company will endeavor to identify various government entities where our intellectual property rights may prove valuable and address the agency on a technical level to potentially contract collaborative research and/or development services contract(s).

Additional Commentaries and remarks

Patents

Nano Cutting Edge Technology Pvt. Ltd. - Nanocet®

Benj — Sun, 03 Dec 2006 13:04:37 +0000

Ticker Id

Web url

http://www.nanocet.org/

Contact Email

info@nanocet.org

Short description

Street address

79 / 87, D.Lad Path, Kalachowki

Zip or postal code

Telephone

+91 - 22 -2371 8238 / 46

Fax

+91 - 22 - 2373 9381

Foundation date

Ceo, president

Number of employees

Long description

NANOCET has mastered a new approach of Material Science and Engineering through Biology. A variety of semiconductor and transition metal nanoparticles have been synthesized using a repertoire of metal interacting microorganisms. These methods are eco-friendly and less energy – intensive as compared to conventional methods.

. Antimicrobial agents
. Cancer hyperthermia
. Targeted drug delivery
. Drug presentation
. Diagnostics
. Use in traditional medicine
. Treatment of pollutants

Additional Commentaries and remarks

Patents

Nanocoatings Pty Ltd

Mon, 02 Apr 2007 15:31:51 +0100

Ticker Id

Web url

http://www.nanocoatings.com.au/

Contact Email

b.ben-nissan@nanocoatings.com.au

Short description

Street address

Strickland St

Zip or postal code

2029

Telephone

61412424123

Fax

Foundation date

Ceo, president

Professor Besim Ben-Nissan

Number of employees

Long description

Synthetic Bone Graft for Biomedical Load- bearing Applications

This new material and its production technique represent a significant advance on the materials currently available for bone graft and spinal implant technology.

The new product, BioAlmog, is a high-strength bone-graft material derived from hydroxyapatite. It has innovative features that give it specific advantages in its mechanical properties, in comparison to other commercially available hydroxyapatite products.

These advantages are due to the conversion treatment, and the nano-coating with carbonate apatite, which uses a novel sol-gel technique. The new bone-graft technology will be of great social benefit, particularly for sufferers of arthritis and related disabling diseases.

Potential uses for the technology include bone-grafting under load-bearing conditions, such as long bones and the spine, and bioactive coatings for artificial joints, such as total hip replacements, knee and dental implants.

When you consider that an estimated 500 million people worldwide have various forms of arthritis, you can see the great potential of BioAlmog to help these people. We developed this technology at UTS, Sydney and are collaborating with UNSW and a university in the UK.

We are now looking to generate further interest, form alliances and gain cooperations from companies and institutions interested to assist bringing this invention onto the market. Contact us at b.ben-nissan@nanocoatings.com.au

Additional Commentaries and remarks

Patents

Nexia Biotechnologies Inc.

Benj — Mon, 21 Aug 2006 15:07:00 +0100

Ticker Id

Web url

http://www.nexiabiotech.com/

Contact Email

Short description

Street address

P.O. BOX 187, Branch Jean-Talon

Zip or postal code

H1S 2Z2

Telephone

514.58-NEXIA, (514.586.3942)

Fax

514.371.7880

Foundation date

Ceo, president

Number of employees

Long description

Spider silk has long been admired by material scientists for its unique combination of high-performance mechanical properties including toughness, strength, lightness, and flexibility. Unfortunately, no one has been able to produce this wonder material in commercial quantities. Nexia is the only company which has successfully produced fibres from recombinant spider silk and is currently in the process of developing commercial quantities of BioSteel using its proprietary transgenic goat technology. Medical device applications of BioSteel-M include wound closure systems like microsutures, surgical meshes, and artificial ligaments such as anterior cruciate ligaments in the knee (ACL). Industrial BioSteel-I applications may include consumer products such as biodegradable fishing line, tennis strings and military applications (soft body armour). Using its transgenic platform technology, Nexia also produces biopharmaceuticals, where it uses its transgenic production system to produce complex proteins that can be used as drugs.

Additional Commentaries and remarks

Patents

Amirta Center for Nanosciences

Benj — Wed, 04 Jul 2007 15:27:46 +0100

Ticker Id

Web url

http://www.aimshospital.org/research/centre-for-nanosciences.html

Contact Email

Short description

Street address

Amrita Institute Of medical Science, Elamakara, Kochi-26

Zip or postal code

682026

Telephone

0484-4001167

Fax

0484-2802020

Foundation date

Ceo, president

Number of employees

Long description

The Amrita Nano Biomedical Engineering Centre, or ANBEC, has been established to conduct research and development work on devices and components at the interface between biology, medicine and engineering, where nanoscience and technology can provide a significant value added benefit over existing technologies. The focus of the centre is research for a variety of medical applications in diagnostics and treatment, including:

* Tissue Nanoengineering
* Nanostructured Membranes and Thin Films
* Nanocomposites
* Surface Nanomodification

Additional Commentaries and remarks

Patents

Abraxis Oncology

Benj — Wed, 16 Aug 2006 18:07:50 +0100

Ticker Id

Web url

http://www.abraxisoncology.com/

Contact Email

Short description

Street address

Zip or postal code

Telephone

1-800-564-0216

Fax

Foundation date

Ceo, president

Number of employees

Long description

Abraxis Oncology was formed with the philosophy that "we will not be bound by current dogma." As it became clear to us that nanotechnology (the science of molecular particles, measured in nanometersbillionths of a meter) would intersect with cellular biology, molecular biology, and medicine, we made the bold commitment that we would make this convergence happen.

The key to next-generation advances is creativity. That means asking the questions that may at first glance appear completely counter-intuitive:

"Should we be working with tumor biology instead of fighting it?"
"Can we turn a drug into a source of food for the tumor?"
"Could tumor blood supply be our access point?"

We have transformed the highly promising concept of protein-bound particle chemotherapeutics into an exciting new patient reality, a next-generation taxane. Through research, innovative science, and creative thinking we are working to redefine the treatment of cancer as we know it.

At Abraxis Oncology, we are employing the best of the best from multiple disciplines. From our national sales force to our marketing team, to our medical department, to support services, and beyond, we are committed to making a difference.

Additional Commentaries and remarks

Patents

GE healthcare ( Formerly Amersham Biosciences Corp )

Benj — Tue, 22 Aug 2006 20:17:27 +0100

Ticker Id

Web url

http://www.gehealthcare.com/

Contact Email

Short description

Street address

800 Centennial Avenue, P.O. Box 1327

Zip or postal code

08855-1327

Telephone

1-800-526-3593

Fax

Foundation date

Ceo, president

Number of employees

Long description

Amersham Biosciences is a world leader in developing systems and solutions for disease research, drug discovery, drug development, and drug manufacture. We are committed to helping our customers unravel life's smallest secrets to achieve some of life's biggest advances. Our 50,000 customers include pharmaceutical, biotechnology and agrochemical companies, as well as research institutes, universities, and medical research centers.

Our vision is to enable molecular medicine by creating solutions that allow scientists to bridge the gap between life science research and healthcare. We develop technologies and products for genomics, proteomics, bioassays, separations, and informatics.

By staying close to industry and academic scientists, we continue our track record of developing innovative tools and products that allow researchers to go beyond the current understanding of disease and develop the next generation of molecular medicines.

The next generation of healthcare will be built on an understanding of the molecular basis for disease. The people at Amersham Biosciences have the commitment, the passion, the leadership, and the vision to help our customers turn the promise of molecular medicine into reality.

Additional Commentaries and remarks

Patents

Digital Bio Technology Co., Ltd.

Benj — Sat, 19 Aug 2006 16:45:42 +0100

Ticker Id

Web url

http://www.digital-bio.com/

Contact Email

Short description

Street address

Seoul National University Institute of Advanced Machinery 1304, San 56-1

Zip or postal code

151-742

Telephone

+82 2 889 7139

Fax

+82 2 885 2267

Foundation date

Ceo, president

Number of employees

Long description

Digital Bio Technology is founded in June, 2000 by Seoul National University Ph.D.'s in the fields of medical, mechanical and electrical engineering with the founding capital of 300 million won. Our company has undergone capital increase and has established itself as a research-oriented company with a total capital of 1.2 billion won and approximately 20 researchers with advanced degrees.

Our company is currently concentrating on a system development of medical and life science, which will lead the future market. Lab-on-a-Chip(LOC), Point-of-Care(POC) and DNA chip analysis system are the main systems which are under developing with the technology of micro plastic chip fabrication and microfluidics. We have recently completed the development and commercialization of a disposable plastic LOC for dilution. And we have also produced prototype of cell counter which differentiates more than two kinds of ells as well as measures the number of cells and PT/APTT assay system which can measure condition of blood coagulation automatically. These two systems are under preparation for commercialization.

Furthermore, with the rapid commercialization of Bio Chips such as DNA/Protein chips, we have succeeded in the development and marketing of scanners(Genoscope DCR 200) necessary for such chip technologies. Also, with our superb MEMS technology as a basis, we plan to invest our resources in the development of small/portable in-vitro POC device, an area in which even technologically advanced nations stay in the quickening period. And all these efforts will lead us to the world-class bio-MEMS comapny.

In the future, Digital Bio Technology aims to develop various equipments that enable to perform many kinds of experimental and analytical processes in the laboratory of companies, universities or the medical institutions more rapidly and more economically. We will also concentrate our effort on developing advanced analysis analysis/experiment systems by combining Bio Technology and Information Technology to estabilish our company as a leader of the Bio-Infra industry and Solution tool provider.

Additional Commentaries and remarks

Patents

Tamil Nadu Agricultural University

chinnamuthu — Fri, 03 Aug 2007 15:55:29 +0100

Ticker Id

Web url

http://www.tnau.ac.in/

Contact Email

chinnamuthu@tnau.ac.in

Short description

Street address

Coimbatore

Zip or postal code

641003

Telephone

91-422-6611254

Fax

91-422-6611454

Foundation date

Ceo, president

Dr.C.Ramasamy

Number of employees

Long description

The Tamil Nadu Agricultural University (TNAU) had its humble beginning as an Agricultural School established in Chennai (erstwhile Madras) during the year 1868. Later, in 1906 it was relocated in the agriculturally progressive district of Coimbatore as an Agricultural College. During 1908, students were first admitted into the Agricultural College for an educational programme leading to Licentiate in Agriculture (L.Ag.).

1920 - B.Sc. (Agri.) three year course started.
1930 - Recognized as a Post-graduate Centre.
1960 - B.Sc.(Agri.) four year course started
1971 - Formation of TNAU.

TNAU, rated as the ‘numero uno’ State Agricultural University in India, continues to maintain its hegemony in academic excellence, including agricultural research, policy interfacing and outreach programmes. TNAU received the ‘Best University Award’ and ‘Best performing University’ from Indian Council of Agricultural Research (ICAR) for 1998.

•The University’s constituent colleges received accreditation from ICAR / AICTE for superior standards of education and infrastructure.
•Well trained faculty in different areas of specialization.
•Largely responsible for the noteworthy and rapid agricultural development of the State of Tamil Nadu.

Vision

•Contribute to improvement in the lives of people depending on agriculture and other rural avocations.
•Maintain excellence in agricultural education and research and in the communication of the results of research to user groups.
•Facilitate collaboration in agricultural education, research, policy interfacing and outreach with national and international institutions.
•Make agriculture in Tamil Nadu and India globally competitive.

Mission

Our mission is to help the farming community in improving their level of living by developing and disseminating technologies, provide impetus to education and research, foster innovation in high productivity and strive to solve problems encountered in attaining self sufficiency in food production of our country.

Additional Commentaries and remarks

Patents

Biosante Pharmaceuticals, Inc.

Benj — Wed, 23 Aug 2006 18:25:15 +0100

Ticker Id

Web url

http://www.biosantepharma.com/

Contact Email

Short description

Street address

111 Barclay Boulevard

Zip or postal code

60069

Telephone

847-478-0500

Fax

847-478-9152

Foundation date

Ceo, president

Stephen M. Simes

Number of employees

Long description

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales.

Additional Commentaries and remarks

Patents

Stemedica Cell Technologies, Inc.

Benj — Sat, 09 Jun 2007 12:39:29 +0100

Ticker Id

Web url

http://www.stemedica.com/about/default.asp

Contact Email

Short description

Street address

5375 Mira Sorrento Pl, Suite 100

Zip or postal code

92121

Telephone

858-658-0910

Fax

858-658-0986

Foundation date

Ceo, president

Number of employees

Long description

These accomplishments are driven by a world class team of prominent scientists, leading clinicians, and executives from successful nutritional, medical and pharmaceutical businesses. The members of the team are located in Centers of Excellence in San Diego, CA, Palo Alto, CA, and Eastern Europe and are directed toward solving the problems associated with this new generation of medicine.

Stemedica Cell Technologies is supported by both individual and institutional funding. Our experienced management team has been responsible for launching several successful companies and the members of our Founders and Scientific Advisory Board have been involved in developing and bringing to market "industry first" medical device, biotech, pharmaceutical and nutraceutical products. We are committed to, and capable of, delivering sustained growth and superior value to our shareholders.

Stemedica is becoming one of the undisputed leaders in engineering the new frontier of adult stem cell methodologies, technologies, therapies and treatment protocols.

Additional Commentaries and remarks

Patents

Velbionanotech

Benj — Tue, 22 Aug 2006 13:03:49 +0100

Ticker Id

Web url

http://www.velbionanotech.com/

Contact Email

info@velbionanotech.com

Short description

Street address

#ff10,first floor, City Point,Infantry Road

Zip or postal code

560 001

Telephone

91-80-41238617

Fax

Foundation date

Ceo, president

Number of employees

Long description

Welcome to future generation products on bionanotechnology at Velbionanotech(VBN) established in March 2002, This was set up to promote Research & Development worldwide, making use of proven latest throughput technologies.VBN analyze genes and proteins for drug discovery. Nanochip designing and microbial Nanochip designs are other areas in our R & D maintained for delivering of drugs on the diseased genes in the human body.
Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured.

VBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules.

We are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery.

VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal.

Additional Commentaries and remarks

Patents

BioNano International Singapore Pte. Ltd.

Benj — Wed, 16 Aug 2006 19:00:28 +0100

Ticker Id

Web url

http://www.bionano.com.sg/

Contact Email

info@bionano.com.sg

Short description

Street address

8 Prince George's Park, NUS Business Incubator

Zip or postal code

118407

Telephone

(65) 6778 9660

Fax

(65) 6778 9220

Foundation date

Ceo, president

Number of employees

Long description

We are active in the basic research, product development and service areas in BioNanotechnology. For example, we are engaged in the research and development of carbon nanotubes, novel solid-state pH acidity probes, electrochemical workstations and nanoparticle-based COD analyzers. These are the cutting edge tools and instruments to be used in environmental analysis, water monitoring, research, medical and health care. We are also one of the leading providers in Asia for analytical instruments. We provide a range of advanced instruments, including electrochemical workstations, on-line COD detectors, pH acidity probes etc.

Several types of biosensing devices have been developed by BioNano International Singapore Pte Ltd combining biotechnology with nanotechnology. Using BioNanoTM Mini-EC Workstation in couple with carbon nanotubes electrode, biomolecules such as uric acid and glucose can be sensitively and selectively detected.

BioNano International Singapore Pte Ltd has a track record of working together with other organizations to develop cost-effective solutions using nanoscience and bioscience to everyday problems. This ensures that all our valued clients can be certain of the continued quality of our products and services. You are welcome to look through our website and see for yourselves how BioNano International Singapore Pte Ltd is "serving the world with bionanotechnology".

Additional Commentaries and remarks

Patents

Nanopartz, a division of Concurrent Analytical Inc.

cschoen — Sat, 04 Nov 2006 11:23:05 +0000

Ticker Id

Web url

http://www.nanopartz.com/

Contact Email

info@nanopartz.com

Short description

Street address

420 Chipeta Way Su 2250

Zip or postal code

84108

Telephone

3077600733

Fax

8772184010

Foundation date

Ceo, president

Shelley Coldiron, PhD

Number of employees

Long description

In partnership with the State University of New York at Binghamton (SUNY), Rice University, and the University of South Carolina, Nanopartz has commercialized the nanoparticle technology. This technology has been developed through funding by the National Defense Center of Excellence for Research in Ocean Sciences (CEROS), Defense Advanced Research Projects Agency (DARPA), National Institute of Health (NIH) as well as private investment and commercial sales.

Additional Commentaries and remarks

Patents

BIOIDENT Technologies, Inc.

Benj — Thu, 07 Dec 2006 10:43:04 +0000

Ticker Id

Web url

http://www.bioident.com/

Contact Email

info@bioident.com

Short description

Street address

3000 Sand Hill Road Building 1, Suite 170

Zip or postal code

94025

Telephone

+1 650 391 4247, 48

Fax

+1 650 561 9303

Foundation date

Ceo, president

Number of employees

Long description

BIOIDENT is the first and only company to combine printed optoelectronics with microfluidics to create a new class of photonic lab-on-a-chip systems, which enable real-time, multi-parameter detection and analysis capabilities. BIOIDENT allows for the first time to integrate full optical readout systems directly onto microfluidic devices. BIOIDENT´s lab-on-chip systems will be used for mobile water and food analysis, chemical and biological agent detection and In-vitro diagnostics. BIOIDENT is a wholly owned subsidiary of NANOIDENT Technologies AG, the technology leader in the development and manufacture of printed organic semiconductor-based photonic solutions.

Additional Commentaries and remarks

Patents

EnviroSystems, Incorporated. (Ecotru)

Benj — Tue, 22 Aug 2006 19:32:27 +0100

Ticker Id

Web url

http://www.envirosi.com/

Contact Email

info@envirosi.com

Short description

Street address

1900 Wyatt Drive, Suite 15

Zip or postal code

95054

Telephone

(800) 374-0017 x 305

Fax

Foundation date

Ceo, president

Number of employees

Long description

The companys breakthrough products include a line of hospital-grade cleansing and disinfecting liquids that reduce the spread of infectious disease without adverse effects to people, equipment or the environment. EcoTru products are the only hospital-grade surface disinfectants on the market that do not require U.S. Environmental Protection Agency handling, warning or precautionary statements. Our Products meet or exceed the efficacy requirements for use in health care, transportation, government, hospitality and consumer markets worldwide.

EnviroSystems focused expertise in the emerging sciences of nano-emulsion technology and membrane biophysics helps position the company at the forefront of the infection control industry at a time when there is rapidly growing awareness of the critical need to reduce biological risks both natural and man-made.

Additional Commentaries and remarks

Patents

Center for Living Technology ( ECLT )

Benj — Fri, 22 Dec 2006 17:14:15 +0000

Ticker Id

Web url

http://bruckner.biomip.rub.de/bmcmyp/Data/ECLT/Public/index_html

Contact Email

Short description

Street address

Zip or postal code

Telephone

Fax

Foundation date

Ceo, president

Number of employees

Long description

The Center will have a wide spectrum of activities to promote study and development of living technology, including:

* Promote, realize and coordinate research activities aimed at living technology.
* Promote, support and organize teaching activities, and high-level training in living technology.
* Offer consulting and research services to agencies, institutions and firms in the area of living technology.
* Sponsor scientific meetings, workshops, publications and exhibitions for the development and diffusion of Center research.
* Coordinate long-term visitors to the Center.
* Organize public seminars, both technical seminars open to the local academic community, and divulgatory seminars aimed at broader public dissemination.

Additional Commentaries and remarks

Patents

GeneOhm Sciences, Inc. ( Acquired by BD )

Benj — Fri, 18 Aug 2006 16:37:48 +0100

Ticker Id

Web url

http://www.geneohm.com/

Contact Email

Short description

Street address

6146 Nancy Ridge Drive

Zip or postal code

92121

Telephone

(858) 334-6300

Fax

(858) 334-6301

Foundation date

Ceo, president

Number of employees

Long description

Established in San Diego, California in 2001, GeneOhm Sciences has assembled an exceptional team including experienced management, talented scientists, top-tier investors and an outstanding Board of Directors. Together we are creating a proprietary platform and portfolio of applications that will allow clinicians to rapidly and inexpensively identify mutations in a patient's genome or detect nucleic acid micro-organisms that cause infectious disease. Our multiplex platform will enable clinicians to apply molecular diagnostics to individual patient care.

Additional Commentaries and remarks

Patents

Cambrios Technologies Corp.

Benj — Thu, 17 Aug 2006 20:03:41 +0100

Ticker Id

Web url

http://www.cambrios.com/

Contact Email

info@cambrios.com

Short description

Street address

2450 Bayshore Parkway

Zip or postal code

94043

Telephone

Fax

Foundation date

Ceo, president

Number of employees

Long description

Cambrios was formed in 2003 to develop commercial applications from the directed-evolution technology invented by the companys founders, Dr. Angela Belcher of MIT and her longtime collaborator, Dr. Evelyn Hu of the University of California at Santa Barbara. Cambrios holds exclusive license rights to Dr. BelcherТ’s technology and is dedicated to the rapid, high-value implementation of these new methods in a variety of applications.

Cambrios is an attractive partner for the electronics industry. Our directed-evolution technology platform is the first practical union of biology and electronics. By applying the techniques of molecular biology to the synthesis and assembly of commercially important materials, Cambrios is able to manufacture electronic components in completely new ways. When bundled with existing manufacturing processes, we believe our technology will enable higher performance at lower cost, and with less impact on the environment.

Cambrios' main business goal is to identify and develop key applications that are uniquely enabled by our technology. The application landscape the company plans to explore includes the synthesis of important materials, process agents for manufacturing, and preparation of nanostructures made of custom materials. In developing these applications, Cambrios looks to partner with innovative companies seeking breakthrough solutions to important commercial problems.

Additional Commentaries and remarks

Patents

Activery Biotech SL ( Activery )

Benj — Sun, 03 Dec 2006 13:24:58 +0000

Ticker Id

Web url

http://www.activery.com/

Contact Email

Short description

Street address

C/Berlin 50

Zip or postal code

08029

Telephone

+34 935 820 152

Fax

+34 935 801 354

Foundation date

Ceo, president

Number of employees

Long description

The basic technology platform of Activery®, is DELOS®, the newest and most promising nanoparticle production method using supercritical fluids (SCF).

Initially patented just as a "method for precipitating finely divided solid particles", further developments based on its unique common denominator led to a significant diversification through two new innovative processes.

• DELOS PLUS for the production of composite materials
• DELOS SUSP for production of nanosuspensions and nanoemulsions

In addition, Activery® possesses extensive capabilities using supercritical fluids with the established PCA process for the production of micro-particles and composite materials.